Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | DGAT2 | Q96PD7 | 8/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | RORB | Q92753 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28107776 | 0.88 | SCN9A (0.59) | ABHD6SCN9AUCHL1BTK | |
| SCHEMBL29739756 | 0.85 | UCHL1 (0.58) | ABHD6SCN9AHTR1AHTR7DGAT2 | |
| SCHEMBL17021263 | 0.85 | UCHL1 (0.58) | ABHD6SCN9AHTR1AHTR7DGAT2 | |
| SCHEMBL17559852 | 0.82 | DGAT2 (0.54) | SCN9ADGAT2 | |
| SCHEMBL17010303 | 0.79 | ABHD6 (0.54) | ABHD6SCN9AUCHL1BTK | |
| SCHEMBL19378993 | 0.79 | HTR2A (0.53) | SCN9ADGAT2 | |
| SCHEMBL15271709 | 0.79 | SCN9A (0.55) | ABHD6SCN9ABTK | |
| SCHEMBL17010307 | 0.78 | ABHD6 (0.46) | ABHD6SCN9AUCHL1BTK | |
| SCHEMBL14862910 | 0.76 | ABHD6 (0.53) | ABHD6SCN9AUCHL1 | |
| SCHEMBL1853855 | 0.75 | FFAR1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200407338-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2020-12-31 | — | — | US | disclosed |
| CN-106103422-B | Isoquinoline derivatives and uses thereof | 普渡制药公司 | 2020-09-18 | — | — | CN | disclosed |
| US-10738026-B2 | Isoquinoline derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3105217-B1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20170057942-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-03-02 | — | — | US | disclosed |
| EP-3105217-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | Purdue Pharma LP (US) | 2016-12-21 | — | — | EP | disclosed |
| CN-106103422-A | Isoquinilone derivatives and application thereof | 普渡制药公司 | 2016-11-09 | — | — | CN | disclosed |
| WO-2015123398-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738026-B2 | Isoquinoline derivatives and use thereof | KCNQ3, KCNQ5, KCNQ4 | ABHD6 3395/4885SCN9A 67/4885HTR1A 413/4885 |
| US-20170057942-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | KCNQ3, KCNQ5, KCNQ4 | ABHD6 3395/4885SCN9A 67/4885HTR1A 413/4885 |
| US-20200407338-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | KCNQ3, KCNQ5, KCNQ4 | ABHD6 3395/4885SCN9A 67/4885HTR1A 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.